APA (7th ed.) Citation

Chipidza, F. E., Alshalalfa, M., Mahal, B. A., Karnes, R. J., Liu, Y., Davicioni, E., . . . Muralidhar, V. (2021). Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clinical Genitourinary Cancer, 19(3), 246. https://doi.org/10.1016/j.clgc.2020.08.004

Chicago Style (17th ed.) Citation

Chipidza, Fallon E., et al. "Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer." Clinical Genitourinary Cancer 19, no. 3 (2021): 246. https://doi.org/10.1016/j.clgc.2020.08.004.

MLA (9th ed.) Citation

Chipidza, Fallon E., et al. "Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer." Clinical Genitourinary Cancer, vol. 19, no. 3, 2021, p. 246, https://doi.org/10.1016/j.clgc.2020.08.004.